Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is one of the largest biopharmaceutical companies globally, headquartered in North Chicago, Illinois. The company specializes in immunology, oncology, neuroscience, aesthetics, and eye care therapeutics, making its news coverage particularly valuable for tracking developments across multiple billion-dollar healthcare markets.
AbbVie news reflects the company diverse therapeutic focus. Immunology updates often include clinical trial results for next-generation autoimmune disease treatments, including JAK inhibitors and other novel mechanisms targeting conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. These announcements can signal shifts in competitive dynamics within the autoimmune drug market.
The oncology division generates news around FDA approvals, clinical trial data, and pipeline developments for cancer therapies. AbbVie cancer portfolio includes treatments for hematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma, with ongoing expansion into solid tumor indications. Drug approval timelines and efficacy data from late-stage trials represent key news catalysts.
Neuroscience news covers developments in migraine treatment and Parkinson disease therapies, including CGRP-targeting drugs and advanced delivery systems. The Allergan Aesthetics division, acquired through AbbVie purchase of Allergan, generates news around cosmetic treatment innovations, market expansion, and competitive positioning in the medical aesthetics space.
Quarterly earnings reports provide insight into segment performance across immunology, oncology, and aesthetics divisions. Strategic announcements regarding acquisitions, licensing deals, and pipeline partnerships appear regularly as AbbVie pursues external innovation to supplement internal research. Bookmark this page to track regulatory decisions, clinical milestones, and strategic moves from one of biopharma largest players.
AbbVie (NYSE: ABBV) will present nearly 65 abstracts, including 15 oral presentations, at the upcoming American Society of Hematology (ASH) annual congress from December 10-13, 2022. The presentations will cover 8 types of blood cancers, highlighting investigational and approved therapies such as epcoritamab and navitoclax. Data aims to showcase advancements in treating chronic lymphocytic leukemia and multiple myeloma. The company emphasizes a commitment to improving patient outcomes in blood cancers, although many therapies are still under evaluation and not yet approved.
AbbVie (NYSE: ABBV) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 8:30 a.m. Central time. Key executives, including Rob Michael and Scott Reents, will participate. A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on innovative medicines across therapeutic areas such as immunology and oncology.
AbbVie celebrated its fourth annual BOTOX® Cosmetic Day, achieving record-breaking participation and sales. The event marked the highest single treatment day in the brand's 20-year history, with over 285,000 site visitors within the first hour. Allē registrations hit a new peak, and BOGO gift cards sold out, exceeding 2021 sales by 20%. The brand experienced a 130% increase in searches for local providers. These metrics reflect heightened consumer interest and satisfaction with BOTOX® Cosmetic, which remains the only FDA-approved treatment for specific facial lines.
On November 9, 2022, AbbVie (NYSE: ABBV) announced its participation in the 4th Annual Wolfe Research Healthcare Conference scheduled for November 15, 2022, at 10:30 a.m. CT. Key executives, including Rob Michael and Jeffrey Stewart, will present virtually. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived session accessible later that day. AbbVie focuses on innovative medicines in various therapeutic areas, such as immunology, oncology, and neuroscience.
AbbVie (NYSE: ABBV) will present 36 abstracts at the American College of Rheumatology's annual meeting (ACR Convergence 2022), highlighting advancements in treatments for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Key data includes long-term safety analyses for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab). Notable presentations cover major adverse cardiovascular events in clinical trials and the impact of second-line therapies on disease control. These findings underscore AbbVie's ongoing commitment to innovation in rheumatology.
AbbVie announced results from its NOVA phase 2 study evaluating AGN-151607 for preventing postoperative atrial fibrillation (POAF) in cardiac surgery patients. Although the primary endpoint was not met, the data indicated a significant 29% relative risk reduction for CABG patients treated with 125 units. Moreover, those aged 65 and older showed a 51% risk reduction. The study also reported lower 30-day rehospitalization rates (8.7% vs. 15.7%) and more patients being atrial fibrillation-free (62.9% vs. 45.1%). Adverse events were similar across treatment groups, highlighting AGN-151607's potential in specific populations.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), expands its Pink Ribbon Strong 365 campaign, dedicated to year-round support for breast cancer patients, survivors, and previvors. The initiative emphasizes education and empowerment, offering resources like the Natrelle Cares Package and the Natrelle Inspires Bra, which donates one bra for every purchase. The campaign also includes an award-winning documentary and partnerships with organizations like METAvivor. Allergan aims to raise awareness and provide comprehensive support beyond Breast Cancer Awareness Month.
Genmab has submitted a Biologics License Application (BLA) to the U.S. FDA for epcoritamab, a bispecific antibody targeting relapsed/refractory large B-cell lymphoma. AbbVie has also validated a Marketing Authorization Application (MAA) for epcoritamab with the European Medicines Agency (EMA). These submissions stem from the EPCORE NHL-1 phase 2 trial, showing the drug's safety and efficacy in treating CD20+ mature B-cell non-Hodgkin lymphoma, a significant medical need exists for these patients. The joint development with AbbVie aims to bring new therapeutic options to market.
AbbVie (NYSE: ABBV) has announced the validation of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for epcoritamab, an investigational treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Concurrently, Genmab has submitted a Biologics License Application (BLA) to the FDA for the same drug. Epcoritamab is supported by results from the EPCORE™ NHL-1 Phase 2 trial and aims to address significant unmet needs in treating B-cell malignancies. This joint effort highlights AbbVie's commitment to advancing oncology care.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
